PILOT. (Med 01) Patient Details (attach Addressograph): , # # $% # -! .//01 2 $ %& '( % $ ) * ##!! %#!! *!! Genotype: HbcAb (core antibody) HAV status
|
|
- Aubrie Burns
- 5 years ago
- Views:
Transcription
1 (#"""(+*#"(#*(#"4#' (Med 01) PILOT Patient Details (attach Addressograph): #!! " $ $ %& '( % $ ) * +# *# ##!! %#!! *!!!! HCV status: HBV status: HAV status PCR: Genotype: HbsAg (surface antigen) HbcAb (core antibody) Any known co-infection: Suspected mode of transmission & Year Any existing risk factors: If IVDU current usage : YES / NO Comments:, # # $%! " &$' % ()(* # -! # - - *- -.//31 2.//01 2
2 OVERVIEW OF HEPATITIS C TREATMENT PATHWAY. DISCHARGE / REFERRED TO HEPATOLOGY CLINIC SUSTAINED VIROLOGICAL RESPONSE POST TREATMENT BLOOD TESTING MONITORING DURING TREASTMENT START TREATMENT PRE TREATMENT ASSESSMENT ARRANGE LIVER BIOPSY/ GENOTYPE 1 /CLINICAL INDICATION PATIENT DECLINED OR NOT SUITABLE FOR TREATMENT CONTINUED TO BE MONITORED CONFIRM DIAGNOSIS & EDUCATION, USS. STAGE OUT PATIENT APPOINTMENTS FIRST APPOINTMENT 2 ND APPOINTMENT 3 RD ASPPOINTMENT 4 TH APPOINTMANE FOURTNIGHTLY APPOINTMENTS FOR 8 WEEKS MONTHLY APPOINTMENTS THERAFTER ( total 24 weeks genotype 2,3,4 + L.V.L.1 +R.V.R., 48 weeks genotype,5,6+h.v.l.l.+c.e.v.r.; or 72 weeks genotype 1 2 WEEKS POST TREATMENT COMPLETION 6 MONTHS POST TREATMENT BLOOD TESTING OUTCOME Education and nurse specialist contact outside of clinic appointments NB. All patients referred receive education, counselling and Ultra Sound Scan on confirmation of diagnosis (Red Star). Patients are then individually assessed if not suitable for treatment they are monitored and continually reassessed (green stars). Blue stars indicate a route through a treatment programme. Patients on the green pathway may enter the start of the blue path if deemed suitable during monitoring. It is possible not all patients will be cured and discharged. Those who do not have a negative Sustained Virological Response will continue monitoring.
3 GUIDELINES FOR TREATING PATIENTS WITH HEPATITIS C. Patient details. Ensure patient details are correct. Request patient contact number. Enter details into data base. Record patients wishes regarding treatment options. Ensure addressograph used on every page. Identify any key workers or shared care input from external agencies i.e. CDAT. If 1 st.dna without notice, letter to patient, check address with referral agency and place back on waiting list. If 2 nd DNA without notice, Discharge from service, complete data base and letter to referral source. Education & Support. Provide full verbal education, regarding disease progression, transmission, symptoms, transmission, precautions, pregnancy, assessments, monitoring, treatment, side-effects and efficacy. Provide patient information leaflet. Provide contact details and telephone number of Nurse Specialist. Ensure details entered into data base. If Blood transfusion < 1991 provides information re: Skipton Fund. Assess patient support mechanisms at home. Letter to referral source. Stage 1 first appointment. Discuss with consultant any concerns or at case conference as required. Arrange next out patient appointment when results are available. Patient details. Ensure patient details and contact number remain unchanged. Enter all new information from appointment into data base. Record patient s wishes regarding treatment options. Ensure addressograph used on every page. Identify any key workers or shared care input from external agencies i.e. CDAT. If 1 st.dna without notice, letter to patient, check address with referral agency and place back on waiting list. If 2 nd DNA without notice, Discharge from service, complete data base and letter to referral source. Education & Support. Assess patient support mechanisms at home. Explain results of previous investigations. Explain Liver Biopsy procedure if necessary. Letter to referral source. Assessment. Complete medical history. Assess possible co-infection. Assess suspected route of transmission. Assess any ongoing recreational drug use. Record medication and drug allergies. Assess / discuss contraception. Assess alcohol and cannabis use. Assess any ongoing Health problems which may impact on treatment i.e. weight loss. Complete general, respiratory and abdominal examinations, record findings. If femoral stab indicated arrange same. Investigations. Ensure patient understands and consents to Investigations. Arrange all base line blood tests, FBC, Co-agulation screen, RBL, Thyroid function tests, Glucose, GGT, Urate & AFP. Arrange any blood test outstanding of Hepatitis Screen, HAV, HBV, HCV-PCR and Genotype, EDTA if genotype 1, 4, 5 or 6. Arrange Ultra Sound Scan of Liver and Abdomen. Ensure all blood forms are identified as high risk. ECG if patient >45yrs of age ( see protocol) Refer cardiology if previous angina/m.i/cva. Refer ophthalmology if known glaucoma / family history. ( see cautions re: treatment) Urine drug testing with consent if necessary. Stage 2 second appointment. Assessment. Assess any ongoing recreational drug use, advise regarding direct / indirect sharing as appropriate. Assess alcohol and cannabis use. Assess current medication. Chose continuing care option, 1 patient for treatment, or 2 on going monitoring, Option 1 (for treatment) Assess suitability for Liver biopsy.( see protocol, platelet count >150, INR <1.5, no current drug use) If patient suitable for treatment but is not for Liver Biopsy (see N.I.C.E guidance No.14) arrange OPD when available. Investigations. Ensure patient understands and consents to Investigations Ensure all blood forms are identified as high risk. Urine drug testing with consent if necessary. Arrange repeat co-agulation screen, FBC and LFT. If option 1 arrange Liver Biopsy if indicated above or option 2 OPD 6months. Discuss with consultant any concerns or at case conference as required Arrange next out patient appointment option 1- when results are available or option 2 6 monthly review. Option 1 (for treatment) Explain biopsy results. Ensure appropriate contraception Re-educate re treatment, side-effects and efficacy. Ensure patient aware of importance of attending OPD. Ensure patient has Specialist Nurse contact details. Letter to referral source. Stage 3 third appointment. Assessment & Investigations Option 1 (for treatment) Ensure no on going recreational drug use. Random urine drug screen if necessary. Present patient to consultant for review for treatment if yes continue, if no return to ongoing monitoring.. Ensure adequate funding available (refer high cost drug budget) Arrange OPD s for treatment ( 24 weeks genotype 2/3, 48 weeks genotype 1,4,5 & 6) Arrange medication availability with pharmacy. Arrange base line blood tests, FBC, INR, LFT
4 Patient details (option 1 & 2) Ensure patient details and contact number remain unchanged. Enter all new information from appointment into data base. Record patients wishes regarding treatment options. Ensure addressograph used on every page. Identify any key workers or shared care input from external agencies i.e. CDAT. If 1 st.dna without notice, letter to patient, check address with referral agency and place back on waiting list. If 2 nd DNA without notice, Discharge from service, complete data base and letter to referral source Education and Support. Starting treatment (option 1) education and support. Ensure appropriate contraception Re-educate re treatment, side-effects and efficacy. Ensure patient aware of importance of attending OPD. Ensure patient has Specialist Nurse contact details. Educate re safe disposal of sharps and provide bin. Demonstrate method of subcutaneous administration of medication. Advise patient take paracetamol at home. Advise patient injection site may become pink. Patient details (option 1 & 2) Ensure patient details and contact number remain unchanged. Enter all new information from appointment into data base. Record patients wishes regarding treatment options. Ensure addressograph used on every page. Identify any key workers or shared care input from external agencies i.e. CDAT. If 1 st.dna without notice, letter to patient, check address with referral agency and place back on waiting list. If 2 nd DNA without notice, Discharge from service, complete data base and letter to referral source. Option 2 (ongoing monitoring) Assess any ongoing recreational drug use advise regarding direct / indirect sharing as appropriate. Assess alcohol and cannabis use. Assess current medication. Assess general health, symptoms. Reassess suitability for Liver biopsy / consultant review for treatment if Yes return to stage 2 assessment. If no arrange OPD 6 months. Discuss with consultant any concerns or at case conference as required Arrange next out patient appointment for 6 monthly review. Stage 4- fourth appointment Assessment and treatment. (option 1) Ensure blood results indicate suitable for treatment (see cautions) Assess and discuss contraception. Arrange doctor to complete prescription. Arrange collection of prescription from pharmacy. Arrange home-visit or appointment to supervise next dose. Provide patient with blood form for FBC and LFT 10days post dose. OPD as per plan. Letter to referral source. Option 2 (ongoing monitoring) Assess any ongoing recreational drug use, advise regarding direct / indirect sharing as appropriate. Assess alcohol and cannabis use. Assess current medication. Assess general health, symptoms. Reassess suitability for Liver biopsy / consultant review for treatment if Yes return to stage 2 assessment. If no arrange OPD 6 months. Discuss with consultant any concerns or at case conference as required Arrange next out patient appointment for 6 monthly review. Stage 5 fifth and subsequent appointments. Option 1 (during treatment) Patients will continue to be reviewed every two weeks for the first 8 weeks of their treatment programme then on a monthly basis providing blood results allow. The duration of treatment is indicated according to genotype. education and support. Ensure appropriate contraception. Ensure patient has Specialist Nurse contact details. Provide information regarding any specific side-effects. Letter to referral source. Assessment and treatment. Ensure blood results indicate suitable for treatment (see cautions) adjust dose of treatment as per protocol. Assess and discuss contraception. Arrange doctor to complete prescription. Arrange collection of prescription from pharmacy. Assess weight loss (expected) Assess appetite, nausea, vomiting. Check injection sites. Assess mood. Assess sleep pattern. Arrange blood test as per plan prior to next appointment. Assess any other side-effects. If HB< 9 consider use of EPO, If neutrophils <1.5 despite dose reduction consider G-CSF> Week 12, genotype 1,4,5 & 6 only blood for EDTA. (early Virological response rate) if >/= 2 log deficit continue if not consultant review re discontinuation of treatment. Random urine drug screen if appropriate. OPD as per plan. Patient details (option 1 & 2) Ensure patient details and contact number remain unchanged. Enter all new information from appointment into data base. Record patients wishes regarding treatment options. Ensure addressograph used on every page. Identify any key workers or shared care input from external agencies i.e. CDAT. Option 2 (ongoing monitoring) Assess any ongoing recreational drug use, advise regarding direct / indirect sharing as appropriate. Assess alcohol and cannabis use. Assess current medication. Assess general health, symptoms. Reassess suitability for Liver biopsy / consultant review for treatment if Yes return to stage 2 assessment. If no arrange OPD 6 months.
5 If 1st.DNA without notice, letter to patient, check address with referral agency and place back on waiting list. If 2nd DNA without notice, Discharge from service, complete data base and letter to referral source. Patient details Ensure patient details and contact number remain unchanged. Enter all new information from appointment into data base. Ensure addressograph used on every page. Identify any key workers or shared care input from external agencies i.e. CDAT. Request return of sharps bin for disposal as per hospital policy. If 1 st.dna without notice, letter to patient, check address with referral agency and place back on waiting list. If 2 nd DNA without notice, Discharge from service, complete data base and letter to referral source. Patient details. Ensure patient details and contact number remain unchanged. Enter all new information from appointment into data base. Ensure addressograph used on every page. Identify any key workers or shared care input from external agencies i.e. CDAT. Request return of sharps bin for disposal as per hospital policy. If 1 st.dna without notice, letter to patient, check address with referral agency and place back on waiting list. If 2 nd DNA without notice, Discharge from service, complete data base and letter to referral source. Letter to referral source. Patient details. Enter all new information from appointment into data base Ensure addressograph used on every page. If 1 st.dna without notice, letter to patient, check address with referral agency and place back on waiting list. If 2 nd DNA without notice, Discharge from service, complete data base and letter to referral source. Letter to referral source. Discuss with consultant any concerns or at case conference as required Arrange next out patient appointment for 6 monthly review. Stage 6-2 weeks post treatment (option 2 continue as above) Investigations & Education. Arrange PCR blood test 2 weeks post treatment completion. Ensure appropriate contraception continues, female patients - 6months, male patients -7 months. Ensure patient has Specialist Nurse contact details. Advise patient of continued future protection against possible re-infection and need for repeat PCR in 6 months. Discuss with consultant any concerns or at case conference as required Arrange OPD when results available and explain result, If negative see stage 7 if positive arrange continued monitoring and support from nurse specialist. Letter to referral source. Stage 7 24 weeks post treatment (option 2 continue as above) Stage 8 discharge. Investigations & Education. Arrange PCR blood test for sustained Virological response (SVR). Ensure appropriate contraception continues, female patients 6months, male patients 7 months post treatment. Ensure patient has Specialist Nurse contact details. Advise patient of need for continued future protection against possible re-infection Discuss with consultant any concerns or at case conference as required Arrange OPD when results available and explain result, if positive arrange continued monitoring and support from nurse specialist, if negative see stage 8. Education. Inform referral source of outcome of treatment +/- GP as per patient instruction. Advise patient of need for continued future protection against possible re-infection. Advice future testing will show antibody positive PCR negative. Discuss with consultant any concerns or at case conference as required Discharge patient from service.
6 HPC: Any previous jaundice: Immunisations: Treatment Abroad: Significant Travel: Previous Blood Transfusions: Skipton fund discussed Other Risk Factors: Yes / No PMHx: Gynae. Hx: Contraception: Drug Hx: Allergies:
7 Social History: Alcohol consumption: Smoker: Yes / No Systems review: Cardiac: Respiratory: Abdominal: C.N.S: Bowel Habits: Current weight/loss/gain: Vomiting: Weight: ON EXAMINATION BP: Pulse: O/E
8 INFORMATION/PATIENT EDUCATION DATE: SEEN BY: VISIT 1 TOPICS DISCUSSED/INFORMATION GIVEN What is Hepatitis? Disease Progression Symptoms Transmission routes Precautions Implications of Alcohol and cannabis use Assessment Process Blood Tests USS Treatment and It s Effects Information Leaflet Supplied Specialist Nurse Contact Number Opportunity for Patients Questions Comments/Concerns: INITIAL INVESTIGATIONS ARRANGED Blood Sampling: FBC, LFT, U&E, HCV, PCR, HCV, GENOTYPE, CLOTTING SCREEN, AFP Arrange USS Abdomen OPD When Results are Available Other: YES/NO COMMENTS: Signature:..
9 DATE: SEEN BY: VISIT 2 INFORMATION GIVEN Explain Results of Investigations Establish if current drug usage Discuss Urine Testing Does Patient Want Treatment? Is Liver Biopsy indicated? If NO Discuss Follow Up Patients Concerns/Questions Answered INITIAL YES/NO YES/NO INVESTIGATIONS ARRANGED Arrange Liver Biopsy, Medical Day Unit if indicated Repeat Clotting Screen Next appointment arranged /52 Or OPD following investigations INITIAL COMMENTS: Signature:..
10 DATE: SEEN BY: VISIT 3 INFORMATION GIVEN Biopsy / investigation Results Explained If For Treatment Recap of Education as on Visit 1 Contraception Method: Side-Effects of Treatment Need for OPD Attendance Follow up appointment for./52 Base line bloods arranged including viral load if required Patients Questions Answered INITIAL COMMENTS: Signature:.. CONSULTANT REVIEW: For Treatment: YES / NO Signature
11 DATE: SEEN BY: VISIT 4 STARTING TREATMENT INFORMATION GIVEN Treatment Schedule Contraception Discussed Sharps Disposal Discussed & Bin supplied Treatment & Side Effects Revisited Patient to Collect Prescription During OPD Demonstrate First Does Administration Instruct Patient to Take Paracetamol at Home Advised to Observe Injection Site Arrange to Supervise Next Dose Ensure Patient has Specialist Nurse Contact Number Patient Questions/Concerns Discussed INITIAL INVESTIGATIONS REQUIRED FBC, LFT & INR Form for 10 Days Time supplied INITIAL COMMENTS: Signature:..
12 APPOINTMENTS DURING TREATMENT DATE : SEEN BY: WEEK: Assess Mood Evidence of Sleep Disturbances Weight Appetite Check Injection Sites Check for Other Side-Effects Repeat Prescription Investigations as per Chart ASSESSMENT Y / N COMMENTS: Signature:..
13 APPOINTMENTS DURING TREATMENT DATE : SEEN BY: WEEK: Assess Mood Evidence of Sleep Disturbances Weight Appetite Check Injection Sites Check for Other Side-Effects Repeat Prescription Investigations as per Chart ASSESSMENT Y / N COMMENTS: Signature:..
14 Genotype 1(L.V.L.) 3, 2, 4 Royal Glamorgan Trust Hospital Ynysmaerdy Llantrisant Rhondda Cynon Taff CF72 8XR Reference: The following appointments have been made for you. If you are unable to attend at any time, then please contact either Miss Vickie Price, secretary on ext 4849 ;Angela Andrew or Pam Hams on (01443) ext 4946 or mobile number: (Angela) (Pam) WEEK DATE TIME START WEEK 2 WEEK 4 WEEK 6 WEEK 8 WEEK 12 WEEK 16 WEEK 20 WEEK 26 WEEK 30 WEEK 48 To be arranged WEEK 52 To be arranged Many Thanks Mrs A Andrew, Nurse Specialist Mrs P Hams, Nurse Specialist For Dr R Alcolado, Consultant Physician Royal Glamorgan Trust Hospital Ynysmaerdy Llantrisant Rhondda Cynon Taff
15 Genotype 1(H.V.L.), 5,6 CF72 8XR Reference: The following appointments have been made for you. If you are unable to attend at any time, then please contact either Miss Vickie Price, secretary on ext 4849 ;Angela Andrew or Pam Hams on (01443) ext 4946 or mobile number: (Angela) (Pam) WEEK DATE TIME START WEEK 2 WEEK 4 WEEK 6 WEEK 8 WEEK 12 WEEK 16 WEEK 20 WEEK 24 WEEK 28 WEEK 32 WEEK 36 WEEK 40 WEEK 44 WEEK 50 WEEK 54 WEEK 74 To be arranged WEEK 78 To be arranged Many Thanks Mrs A Andrew, Nurse Specialist Mrs P Hams, Nurse Specialist For Dr R Alcolado, Consultant Physician
16 PONTYPRIDD & RHONDDA NHS TRUST GASTROENTEROLOGY HEPATITIS C TREATMENT MONITORING DATE HCV PCR AFP SIGNATURE COMMENTS LIVER BIOPSY RESULT DATE PERFORMED STAGE GRADE COMMENTS
17 WEEK DATE WEIGHT Hb WBC Neu Plt ALT AST BIL GGT TSH URATE T4 SIG COMMENTS ADDITIONAL INFORMATION/COMMENTS
18 TABLE OF INVESTIGATIONS REQUIRED DURING HEPATITIS C TREATMENT PROGRAMME Genotype 3, 2 4, L.V.L.1 DATE WEEK HCV PCR GENOTYPE HBC HAC AFP CLOTTING SCREEN FBC U & E LFT T4 URATE GLUCOSE OTHER 1 ST VISIT X X X X X X X X X X X X 2 ND VISIT X 3 RD VISIT TX COM X X WEEK 2 X X WEEK 4 X X X RVR(LVL 1 WEEK 6 X X WEEK 8 X X X X X X WEEK 12 X X X X X WEEK 16 X X X X WEEK 20 X X X X X WEEK 26 X X X X WEEK 48 X COMMENTS:
19 TABLE OF INVESTIGATIONS REQUIRED DURING HEPATITIS C TREATMENT PROGRAMME Genotype 1, 4, 5 DATE WEEK HCV PCR GENOTYPE HBC HAC AFP CLOTTING SCREEN FBC U & E LFT T4 URATE GLUCOSE OTHER 1 ST VISIT X X X X X X X X X X X X 2 ND VISIT X 3 RD VISIT TX COM X X WEEK 2 X X WEEK 4 x X X X WEEK 6 X X WEEK 8 X X X X X X WEEK 12 X X X X X WEEK 16 X X X X WEEK 20 X X X X X WEEK 24 x X X X X WEEK 28 X X X WEEK 32 X X X X X X WEEK 36 X X X WEEK 40 X X X X WEEK 44 X X X X X WEEK 48 X X X X WEEK 50 X X X X WEEK 74 X COMMENTS:
20 AUDIT OF ALL PHASES OF HEPATITIS C TREATMENT PROGRAMME FOR GASTROENTEROLOGY NURSING SERVICES, PONTYPRIDD AND RHONDDA NHS TRUST HOSPITAL:. AUDIT PERIOD: V I S I T No of X s Patient details complete Contact Number available GP details complete Source of referral evident HCV genotype known HBV status known HAV status known Issue of co-infection addressed Suspected transmission details complete Existing risk factors addressed History take documentation complete Diagnosis explained Disease progression explained Signs and symptoms explained Modes of transmission explained Necessary precautions explained Alcohol abstention explained Assessment process explained Treatment and side effects explained USS explained Patient information booklet supplied CNS contact number provided Section signed and dated V I S I T 2 Blood results explained USS results explained Any current drug usage addressed Evidence of patient consent to treatment Liver biopsy explained Section signed and dated V I S I T 3 Biopsy results explained Evidence of education update Contraception discussed Treatment discussed Side effects discussed OPD attendance discussed Treatment start date set Treatment appointment schedule arranged Section signed and dated V I S I T 4 Sharps disposal discussed
21 Treatment and side-effects information given First dose administration given Injection site care information given Second dose under supervision Section signed and dated V I S I T S D U R I N G T R E A T M E N T Mood assessed Sleep pattern assessed Patient weight record Appetite addressed Other side-effects if experience addressed Investigations as per plan Visits signed and dated R E S U L T S M O N I T O R I N G Patient details complete Investigations conducted as per table Results table completed for every visit Entries signed and dated Number of ticks: Row A Total = Number of ticks: Row B Total = For each column, count all the actual ticks and the total are entered into Row A. The total number of all potential (not including any N/A s) is entered into Row B. These numbers are then totalled and transferred to the calculation at the end.
22 V I S I T No of X s Patient details complete Contact Number available GP details complete Source of referral evident HCV genotype known HBV status known HAV status known Issue of co-infection addressed Suspected transmission details complete Existing risk factors addressed History take documentation complete Diagnosis explained Disease progression explained Signs and symptoms explained Modes of transmission explained Necessary precautions explained Alcohol abstention explained Assessment process explained Treatment and side effects explained USS explained Patient information booklet supplied CNS contact number provided Section signed and dated V I S I T 2 Blood results explained USS results explained Any current drug usage addressed Evidence of patient consent to treatment Liver biopsy explained Section signed and dated V I S I T 3 Biopsy results explained Evidence of education update Contraception discussed Treatment discussed Side effects discussed OPD attendance discussed Treatment start date set Treatment appointment schedule arranged Section signed and dated V I S I T 4 Sharps disposal discussed Treatment and side-effects information given First dose administration given Injection site care information given Second dose under supervision Section signed and dated
23 V I S I T S D U R I N G T R E A T M E N T Mood assessed Sleep pattern assessed Patient weight record Appetite addressed Other side-effects if experience addressed Investigations as per plan Visits signed and dated R E S U L T S M O N I T O R I N G Patient details complete Investigations conducted as per table Results table completed for every visit Entries signed and dated Number of ticks: Row C Total = Number of ticks: Row D Total = Columns C & D are calculated as for A & B. Data for A, B, C & D are entered into The equation below. The total then demonstrates percentage of compliance to Hepatitis C treatment programme based on a sample of 20 patients receiving the service. % compliance = (A + C) / (B + D) x 100 therefore A+C = x 100 = % B+D Whereby an X has been entered into a section this will provide direction to areas of The service, which will be revisited and assessed for possible improvement.
24 AUTHORS Angela Andrew, Specialist Nurse Gastroenterology. Pam Hams, Specialist Nurse Gastroenterology, Dr Ruth Alcolado, Consultant Physician. Victoria Price, Secretary Gastroenterology. Jayne Gibbs Administration Support REFERENCES The National Institute for Health and Clinical Excellence (2000), Guidance On The Use Of Interferon Alpha for Hepatitis C. Technology appraisal Guidance - No. 14. NICE. London. ABBREVIATIONS USED IN PATHWAY. AFP Alpha-fetoprotein ALT Alanaline Transaminase AST Aspartate amino transferase BIL Total Bilirubin BP Blood Pressure. CDAT-Community Drug and Alcohol Team. CNS Central Nervous System CVA Cerebral Vascular Accident. DHx Drug History ( prescribed and recreational) DNA Did Not Attend. ECG Electrocardiograph. EDTA Quantatative PCR. FBC Full Blood Count. GGT Gamma-glutamyl transpeptidase. GP General Practitioner HAV Hepatitis A HB Haemoglobin HBV Hepatitis B HCV Hepatitis C HPC History of Presenting Complaint Hx History. INR International Normalised Ratio. IVDU - Intravenous Drug Use LFT Liver Function Tests MI Myocardial Infarction. NEU Neutrophils. OPD Out Patient Department appointment. PCR Polymease Chain Reaction. PLT Platelets. PMH Past Medical History SIG Signature. T4- Thyroxine TSH Thyriod-stimulating hormone. U&E Urea and Electrolyte. USS Ultra Sound Scan. WBC Wight Blood Cell Count.
EAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationSHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised
More informationPREOPERATIVE ANAEMIA PATHWAY
PREOPERATIVE ANAEMIA PATHWAY Surname: Unit No. Forename: DOB: / / Age: NHS Number: Likes to be called: Address: Tel. No. Religion/Spirituality: GP Name: GP Practice: Planned Operation: Postcode: Mobile
More informationAbnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital
Abnormal LFTs in migrant populations Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital www.migrationobservatory.ox.ac.uk Migrants in London Migrants in London Migrants in London Common liver
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationLFTs: an update A MacGilchrist PLIG meeting 31st January 2019
LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant
More information02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical POOLE HOSPITAL NHS FOUNDATION TRUST
Service Specification No. Service Commissioner Leads 02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical Provider Lead POOLE HOSPITAL NHS FOUNDATION TRUST Period 1 April 2013 to 31
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationEssential Shared Care Agreement Naltrexone
In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy
More informationAmbulatory Emergency Care Pathways. Painless Obstructive Jaundice
Ambulatory Emergency Care Pathways Painless Obstructive Jaundice Effective Date: December 2011 Content Summary Ref Title Description 1 Condition Details Identifies pathway details and clinical sign-off
More informationPrescribing Framework for Naltrexone in Alcohol Relapse Prevention
Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient
More informationDEPARTMENT OF GENITO-URINARY MEDICINE HEPATITIS B
DEPARTMENT OF GENITO-URINARY MEDICINE MAIN TRANSMISSION ROUTES HEPATITIS B Sexual transmission Occurs in unvaccinated/non immune men who have sex with men and correlates with multiple partners, unprotected
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationSuspected Deep Vein Thrombosis (DVT) Assessment
CHI no... First name... DOB... /... /... Last name... Sex: c M c F Address...... Telephone... or attach addressograph label here Hospital/Location: c Hairmyres c Monklands c Wishaw Other (specify)... Ward/Base...
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for referral 3. Raised ALT +/- GGT p3 4. Non alcoholic fatty liver
More informationEssential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a
More informationPREOPERATIVE ANAEMIA PATHWAY
PREOPERATIVE ANAEMIA PATHWAY Surname: Patient ID No. Forename: DOB: / / Age: NHS Number: Likes to be called: Address: Tel. No. Religion/Spirituality: Next of Kin: Name GP Name: GP Practice: Planned Operation:
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationIntestinal Failure Referral Form
Intestinal Failure Referral Form This form must be completed in full and emailed to UCLH.IFReferrals@nhs.net or call 07958 263178. Please complete all sections of the form. Please note that incomplete
More informationUHSM ED Pathway ELDERLY FALL / COLLAPSE
UHSM ED Pathway ELDERLY FALL / COLLAPSE Patient name / Pathway for patients who require assessment in ED after a fall or collapse Note: - It can be used if the patient has also sustained a minor head injury
More informationFulvestrant (Faslodex )
In Partnership with Health Authorities & GPs continuing-care guidelines Fulvestrant (Faslodex ) in the Management of Postmenopausal Women with Advanced Breast Cancer Approved by: Date approved: October
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationSouth Yorkshire, Bassetlaw and North Derbyshire Cancer Alliance
South Yorkshire, Bassetlaw and North Derbyshire Cancer Alliance Patient Details: Patient Name Address DOB Home Tel. No. Mobile Tel. No. Preferred Tel. No. Main Spoken Language Transport needed? Registered
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationHepatitis C: Ribavirin/Pegylated Interferon combination therapy
Hepatitis C: Ribavirin/Pegylated Interferon Introduction This information sheet is for people who want to know more about the ribavirin/pegylated interferon combination treatment for Hepatitis C (HCV).
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationTREATMENT INTENT Disease modification- see European LeukemiaNet (ELN) 2013 guidelines for treatment goals.
BOSUTINIB INDICATION Licensed / NICE TA401 (BLUETEQ required) The treatment of adult patients with chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML)
More informationPlease inform the Diabetes Nurse Specialist that this patient has been admitted within 24hrs of admission.
Adult Diabetic Ketoacidosis Care Bundle (V1. Issued October 2014 Review October 2015) Improving patient care This pack includes: DKA Management Guideline Name: (Patient Addressograph) DOB: Hospital No:
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE SHARED CARE AGREEMENT
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE SHARED CARE AGREEMENT NALTREXONE 50mg TABLETS For Opioid Relapse Prevention (in formerly opioid dependent patients) This shared care agreement is aimed at all
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Drug: Methotrexate Introduction Indication: Licensed: Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, mild to moderate
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationCardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE
Cardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE Drug: RILUZOLE Protocol number: CV 39 Indication: AMYOTROPHIC LATERAL SCLEROSIS (ALS) General Guidance
More informationOne Stop Prostate Biopsy Protocol Author Consultation Date Approved
One Stop Prostate Biopsy Protocol Author Consultation Date Approved Urology Nurse Practioner PROTOCOL FOR MEN ATTENDING A ONE STOP PROSTATE BIOPSY CLINIC RATIONALE Prostate cancer is the most common cancer
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationNICE Guidance. Suspected Cancer in Adults COLORECTAL (2WW)
NICE Guidance Suspected Cancer in Adults COLORECTAL (2WW) Date of Referral: Short date letter merged Name: Full Name DOB: Date of Birth NHS No NHS Number Attach this form to the e-referral within 24 hours
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationPulmonary Embolism Pathway
Pulmonary Embolism Pathway Ambulatory Care Pathway Dr. A. Zafar, Dr. A. Rehman, Dr. T. Malik September, 2011. Patient Identification Label Pulmonary Embolism Pathway Clinical History Comments Hospital
More informationGuidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationSOMATROPIN ( Genotropin, Humatrope, Norditropin,
Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300
More informationReferral Form CPFT Chronic Fatigue Syndrome / Myalgic Encephalomyelitis Service (CFS/ME) for Adults
Referral Form CPFT Chronic Fatigue Syndrome / Myalgic Encephalomyelitis Service (CFS/ME) for Adults Please note: Failure to include all Information required may result in your referral being rejected.
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)
E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More information1. SYNOPSIS. AWB-ML21645 Date: April 20, 2016 Title of the observational study
1. SYNOPSIS AWB-ML21645 Date: April 20, 2016 Title of the observational study INVESTIGATORS SPONSOR Noninterventional study on the quality assurance of the therapy of chronic hepatitis C with Peg-(40kd)-Interferon
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationDrug Induced Liver Injury (DILI)
Drug Induced Liver Injury (DILI) Aisling Considine- Consultant Hepatology Pharmacist. King s College Hospital NHS Foundation Trust aislingconsidine@nhs.net Drug Induced Liver Injury /Disease Acute Liver
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationCharlson Comorbidities (please TICK all that apply)
Medical Clerking On Call Consultant: Date: Time: Grade: Specialty: Age: Presenting Complaint: CLINICIAN: GRADE: DATE/TIME: Past Medical History: Charlson Comorbidities (please TICK all that apply) Cancer
More informationInitiation of Clozapine Treatment Community Patients
Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A Initiation of Clozapine Treatment for Patients in the
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationSELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)
SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT MDT Lead Clinician ASWCN TAUNTON AND SOMERSET Taunton Lung MDT (11-2C-1) - 2011/12 Dr Sarah Foster Compliance Self Assessment LUNG MDT
More informationGG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationPrescribing Framework for Galantamine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationHEPATITIS HEPATITIS A. The Hepatitis Alphabet HOW DOES ONE GET HEPATITIS A? THE SYMPTOMS of HEPATITIS A
HEPATITIS Hepatitis is an inflammation of the liver that can be caused by viruses, chemicals or drugs. The two most common types of viral hepatitis are Hepatitis A (also called infectious hepatitis ) and
More informationShared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults
Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no:
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationDimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients
Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) 529 5715 Email: ian.pomeroy@thewaltoncentre.nhs.uk
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationDr Katharine Cartwright
Fifth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Dr Katharine Cartwright Leicester Royal Infirmary Wednesday 3 October 2012, One Great
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationLeflunomide (Arava )
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationLapatinib and Capecitabine Therapy
Lapatinib and Capecitabine Therapy This protocol should be read in conjunction with NCCP protocol 00216 Capecitabine Monotherapy. INDICATIONS FOR USE: INDICATION Treatment of adult patients with breast
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationCancer of Unknown Primary Service
Cancer of Unknown Primary Service Dr Maurice Fernando Consultant In Specialist Palliative Care and CUP lead Doncaster and Bassetlaw Hospitals NHS FT Wakefield meeting -14-07-2016 CUP service CUP MDT
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP
ESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP Dermatology/ Haematology/ Gastroenterology/ Neurology/ Ophthalmology/ Respiratory/
More informationNCCP Chemotherapy Regimen. Olaparib Monotherapy
Olaparib INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Maintenance treatment of adult patients with platinum -sensitive relapsed BRCAmutated (germline and/or somatic) - high
More informationSALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department
More informationFactsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)
North Central London Joint Formulary Committee Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C) Start date: September 2018 Review date: September 2021 Document
More informationSHARED CARE AGREEMENT: METHOTREXATE S/C
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) and BSR Guideline for disease-modifying anti-rheumatic drug (DMARD) therapy (available at www.rheumatology.org.uk/resources/guidelines/bsr_guidelines.aspx
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationTrust Protocol for the Administration of Intravenous Methylprednisolone for Thyroid Eye Disease A Protocol. The Clinical Investigation Unit (CIU)
A Protocol For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name and job title of document author s Line Manager: Supported by:
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationCommunity Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti-Cancer Treatment Protocol. Abiraterone. PROCTOCOL REF: MPHAABIRA (Version No: 1.
Systemic Anti-Cancer Treatment Protocol Abiraterone PROCTOCOL REF: MPHAABIRA (Version No: 1.0) Approved for use in: The treatment of metastatic castration resistant prostate cancer in adult men who are
More informationFractured Neck of Femur Proforma Orthopaedic Unit. First name: Registration no: Date of birth: Age:
Fractured Neck of Femur Proforma Orthopaedic Unit Date: Surname : ED doctor s name: Time seen: Orthopaedic admitting doctor s name: Time seen: Presenting complaint and history of fall: First name: Registration
More information